1. Home
  2. 340B Drug Pricing Program
  3. Program Updates
  4. 2021 340B Covered Entity Purchases

2021 340B Covered Entity Purchases

In calendar year 2021, 340B covered entities purchased $43.9 billion in covered outpatient drugs under the 340B Program. This program enables safety-net providers to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services for the communities that they serve. The information below details the aggregate 340B purchases by covered entity type in 2021. 

Entity Type 2021 Total Purchases
Disproportionate Share Hospitals $34,288,472,705
Health Center Programs $2,215,221,250
Children's Hospitals $1,330,248,212
Rural Referral Centers $1,174,151,155
Ryan White HIV/AIDS Program Part A $1,151,719,110
Sexually Transmitted Disease Clinics $871,036,833
Critical Access Hospitals $620,923,559
Ryan White HIV/AIDS Program Part C $519,299,391
Sole Community Hospitals $451,594,319
Free-standing Cancer Centers $304,098,033
Ryan White HIV/AIDS Program Part B $234,735,497
Ryan White Part B AIDS Drug Assistance Program (ADAP) Direct Purchase Option $230,807,198
Comprehensive Hemophilia Treatment Centers $192,106,843
Federally Qualified Health Center Look-Alike Program $173,025,319
Family Planning Clinics $74,912,338
Ryan White HIV/AIDS Program Part D $43,419,350
Tribal Contract/Compact with IHS (P.L. 93-638) $30,973,328
Tuberculosis Clinics $4,278,525
Urban Indian Hospitals $1,154,612
Black Lung Clinics $189,963
Ryan White Part B ADAP Rebate Option $23,336
Native Hawaiian Heath Care Programs $23,305
Total $43,912,414,182

Source: 340B Prime Vendor Program, August 12, 2022

Note: These purchase data are provided by the 340B Prime Vendor Program and do not capture the entire universe of 340B Program purchases (e.g., the Prime Vendor Program does not collect all direct purchases). The Prime Vendor Program was established pursuant to section 340B(a)(8) of the Public Health Service Act for price negotiation, distribution facilitation, and other activities in support of the 340B Drug Pricing Program. It is managed by Apexus through a contract with the Health Resources and Services Administration. These figures are accurate as of Aug. 12, 2022. The purchase data provided is a culmination of transactional data captured by the Prime Vendor Program at a given point in time. The totals reflected in this chart may change, as the 340B Prime Vendor Program is constantly reviewing and updating the data as transactions occur, and there are times when adjustments to invoices are made which impact the total purchases reported. Entity organizations are defined at section 340B(a)(4) of the Public Health Service Act. 

Date Last Reviewed: